Processa Pharmaceuticals (PCSA) Research & Development (2012 - 2026)
Processa Pharmaceuticals' (PCSA) quarterly Research & Development came in at $1.8 million in Q1 2026, up 13.89% YoY from $1.6 million in Q1 2025, and down 14.4% on a QoQ basis from $2.1 million in Q4 2025.
Processa Pharmaceuticals (PCSA) Research & Development (2012 - 2026) Analysis & Trends
Processa Pharmaceuticals (PCSA) has 15 years of Research & Development data on file, last reported at $1.8 million in Q1 2026.
- Quarterly Research & Development rose 13.89% year-over-year to $1.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.0 million (up 9.74% YoY) and the FY2025 annual result came in at $7.8 million, up 7.45% from the prior year.
- Research & Development retreated to $1.8 million in Q1 2026, from $2.1 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $3.2 million in Q4 2022 to a low of $1.2 million in Q3 2023.
- A 5-year average of $2.0 million and a median of $1.7 million in 2024 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2023 — Research & Development tumbled 63.28% — and 2024, when it surged 98.61%.
- Tracing PCSA's Research & Development over 5 years: stood at $3.2 million in 2022, then tumbled by 58.39% to $1.3 million in 2023, then increased by 29.66% to $1.7 million in 2024, then climbed by 23.43% to $2.1 million in 2025, then decreased by 14.4% to $1.8 million in 2026.
- The last three Research & Development figures came in at $1.8 million (Q1 2026), $2.1 million (Q4 2025), and $1.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Processa Pharmaceuticals | 5.93 Mn | 5.93 Mn | - | 649,877.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.81 Mn |
| Dec 31, 2025 | 2.11 Mn |
| Sep 30, 2025 | 1.66 Mn |
| Jun 30, 2025 | 2.45 Mn |
| Mar 31, 2025 | 1.59 Mn |
| Dec 31, 2024 | 1.71 Mn |
| Sep 30, 2024 | 2.29 Mn |
| Jun 30, 2024 | 1.73 Mn |
| Mar 31, 2024 | 1.54 Mn |
| Dec 31, 2023 | 1.32 Mn |
| Sep 30, 2023 | 1.15 Mn |
| Jun 30, 2023 | 1.69 Mn |
| Mar 31, 2023 | 1.63 Mn |
| Dec 31, 2022 | 3.17 Mn |
| Sep 30, 2022 | 3.14 Mn |
| Jun 30, 2022 | 3.14 Mn |
| Mar 31, 2022 | 2.04 Mn |
| Dec 31, 2021 | 2.07 Mn |
| Sep 30, 2021 | 1.72 Mn |
| Jun 30, 2021 | 1.61 Mn |